In the last 30 years, there have been easier to prescribe, safer antidepressants for major depressive disorder, as well as the introduction of easy-to-learn approaches to therapy, but 40% or so of people suffering from depression aren’t in treatment, explained Michael Thase, MD, professor of psychiatry and director of the Mood and Anxiety Program at the University of Pennsylvania.
Michael Thase, MD, professor of psychiatry and director of the Mood and Anxiety Program at the University of Pennsylvania, explains how major depressive disorder is typically treated, as well as the greatest challenges in treating the disorder.
TranscriptHow is major depressive disorder typically treated?
The largest public health advance in the care of depression in the last 30 years was the introduction of easier to prescribe, safer antidepressants that made it possible for many depressed patients to be treated in primary care. At the same time, relatively easy-to-learn approaches to therapy involving core interpersonal issues or cognitive behavioral strategies also became increasingly available.
Now, these treatments aren’t as widely and broadly available as pharmacotherapy, and, sometimes, they’re used in combination with pharmacotherapy. But, between the newer generation antidepressants and the focused psychotherapies, probably 6 or 7 out of 10 depressed people seeking care in the outpatient side of the world can get better within 3 or 4 months.
What are the greatest challenges in treating this disorder?
So, the number one challenge is that, at any moment in time, 40% or so of people suffering from depression aren’t in treatment whatsoever. So, ways of making the benefits of treatment more broadly known and more accessible to people is one challenge. Another challenge, of course, is for the people who seek treatment but for whom our standard treatments aren’t effective. And there’s a subset, maybe as large as 20% or 25% for whom our standards medications and standard therapies don’t work.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More